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ttp://dx.doi.org/10.1016/j.ajpath.2013.07.021Preeclampsia is characterized by hypertension and proteinuria in pregnant women. Its exact cause is
unknown. Preeclampsia increases the risk of maternal and fetal morbidity and mortality. Although
delivery, often premature, is the only known cure, early targeted interventions may improve maternal and
fetal outcomes. Successful intervention requires a better understanding of the molecular etiology of
preeclampsia and the development of accurate methods to predict women at risk. To this end, we tested
the role of miR-210, a miRNA up-regulated in preeclamptic placentas, in ﬁrst-trimester extravillous
trophoblasts. miR-210 overexpression reduced trophoblast invasion, a process necessary for uteropla-
cental perfusion, in an extracellular signaleregulated kinase/mitogen-activated protein kinasee
dependent manner. Conversely, miR-210 inhibition promoted invasion. Furthermore, given that the
placenta secretes miRNAs into the maternal circulation, we tested if serum expression of miR-210 was
associated with the disease. We measured miR-210 expression in two clinical studies: a case-control study
and a prospective cohort study. Serum miR-210 expression was signiﬁcantly associated with a diagnosis
of preeclampsia (PZ 0.007, area under the receiver operator curvesZ 0.81) and was predictive of the
disease, even months before clinical diagnosis (P < 0.0001, area under the receiver operator curveZ
0.89). Hence, we conclude that aberrant expression of miR-210 may contribute to trophoblast function
and that miR-210 is a novel predictive serum biomarker for preeclampsia that can help in identifying at-
risk women for monitoring and treatment. (Am J Pathol 2013, 183: 1437e1445; http://dx.doi.org/
10.1016/j.ajpath.2013.07.021)Supported by The Penn Presbyterian George L. and Emily McMichael
Harrison Fund for Research in Obstetrics and Gynecology and grant
1R03HD069742 (N.S.), NIH grants 2-R01-NS054794-06 and 5-R01-
HL097800-04 (J.B.H.), DARPA grant 12-DARPA-1068 (J.B.H), and National
Human Genome Research Institute training grant T32HG000046 (A.O.O.-G.).
L.A. and A.O.O.-G. contributed equally to this article.Hypertensive disorders of pregnancy (HDPs) have a large
impact on maternal and fetal health. Preeclampsia, a multi-
system disorder characterized by maternal hypertension and
proteinuria, is one of the most common complications of
pregnancy, with an occurrence of 5% to 10%.1e3 Although
preeclampsia confers speciﬁc maternal risks, including end-
organ injury, it also increases the risk of fetal and neonatal
morbidity. Despite extensive research, the exact cause of
preeclampsia is unknown. Current theories include defects
in placental implantation,4 alterations in angiogenesis,5,6
and dysregulation of plasma volume.7 In addition,
randomized controlled trials targeting placental vasocon-
striction have been relatively unsuccessful.8,9 Delivery
remains the only effective cure.
Recent research on the initiation of pathogenesis has
focused on trophoblast/placental dysfunction. Implantationstigative Pathology.
.and successful placentation ensue from a distinct set of
cellular events, including attachment of the embryo to the
endometrial wall, proliferation and migration of embryonic
trophoblast cells, and invasion of the trophoblast cells into
the endometrium.7,10 Remodeling of the uterine spiral
arteries by the invading extravillous trophoblast (EVT)
cells increases vessel diameter and results in uteroplacental
perfusion. Abnormalities in this process can cause placental
hypoxia, resulting in trophoblast dysfunction and, pre-
sumably, preeclampsia.11 Therefore, identifying how this
Anton et alprocess is regulated is central to understanding the patho-
physiological characteristics of preeclampsia.
Preeclampsia is often diagnosed in the third trimester of
pregnancy. However, the underlying disorder is likely
present much earlier. Identifying those at risk for developing
preeclampsia before the onset of clinical symptoms may
provide valuable insight into the etiology of the disease and
improve health outcomes. Several biomarkers for pre-
eclampsia have been suggested.12,13 Unfortunately, most of
these biomarkers lack sufﬁcient sensitivity and/or speciﬁcity
for widespread adoption into clinical use. Furthermore, most
studies have focused on proteins and metabolites in
bioﬂuids. However, few studies have evaluated circulating
nucleic acids, such as miRNAs, which are becoming
a powerful class of biomarkers for a wide variety of
physiological states and diseases,14,15 as biomarkers for
preeclampsia.
miRNAs are small (approximately 22 nucleotides), non-
coding RNAs that play a critical role in post-transcriptional
gene regulation.16 miRNAs regulate diverse cellular pro-
cesses and target up to 60% of human genes.16,17 By binding
to complementary sites in their target mRNA, miRNAs
destabilize the transcript and repress translation.16 miR-210
is a common hypoxia-induced miRNA involved in a
myriad of biological processes, including angiogenesis, cell
differentiation, cell cycle regulation, proliferation and
growth, inﬂammation, DNA damage repair, and mitochon-
drial metabolism.18e20 Because many of these processes
have been shown to be abnormally regulated in preeclampsia,
recent studies have evaluated miR-210 expression in pre-
eclampsia.21e24 These studies found increased miR-210
expression in preeclamptic placentas. One study suggests
that miR-210 levels are elevated in the plasma of women with
preeclampsia at delivery.24 However, it is unknown whether
miR-210 levels are elevated before the clinical presentation
of symptoms. Thus, whether miR-210 levels can be a clini-
cally useful predictor of the development of this disease and,
hence, could be used to risk stratify women for interventions
remains unstudied.
We hypothesized that dysregulated miR-210 expression
may contribute to trophoblast dysfunction, and because the
placenta secretes miRNAs during pregnancy,25 we also
posited that miR-210 levels will be elevated at the time of
clinical diagnosis of the disease andmonths before the onset of
clinical symptoms. To test our hypothesis, we ﬁrst determined
the biological effect of miR-210 on trophoblast function. We
tested the impact of inhibiting and overexpressingmiR-210 on
EVT invasiveness and investigated the underlying signaling
pathwaymediating this effect. To determinewhethermiR-210
levels are altered with the clinical onset of disease, we
measured serum miR-210 expression in maternal blood from
a case-control study of women with preeclampsia. To deter-
mine whether miR-210 levels could predict preeclampsia
months before the clinical onset of symptoms, we assessed
miR-210 levels inmaternal blood collected in the early second
trimester of pregnancy in asymptomatic, low-risk women.1438Materials and Methods
Cell Culture
Primary EVTs were isolated from ﬁrst-trimester villous
tissue using a protocol that has been established and well
documented by researchers.26e28 Brieﬂy, ﬁnely minced
chorionic villi collected from de-identiﬁed elective ﬁrst-
trimester pregnancy termination tissues (<12 weeks) were
cultured at 37C in RPMI 1640 medium containing 20%
charcoal-stripped (steroid-free) fetal bovine serum (FBS).
EVT cells, which outgrow from attached villous fragments,
were separated from villous tissue during washing and
passaging of the cells. The isolated EVT cells were cultured
and propagated in RPMI 1640 medium containing 20%
FBS. The EVT cells used in our experiments were charac-
terized by immunostaining for trophoblast cell markers,
cytokeratins 7, 8, and 18, and integrin a-1.26,29,30 These
results are similar to those obtained by other investigators
using the same EVT isolation methods and conﬁrm the
purity of the EVT cell preparations.27,28
EVT Transfection
EVT cells were plated at 1  105 cells per well in 6-well
plates in antibiotic-free RPMI 1640 media containing 20%
FBS. The cells were transfected with 40 nmol/L miRNA
mimics or 60 mmol/L morpholino antisense oligos the next
day. Hsa-miR-210 and miR-neg (nontargeting control)
miRNA mimics were purchased from Life Technologies
(Carlsbad, CA). The morpholino antisense oligo (MO)-210
(50-AGATCAGCCGCTGTCACACGCACAG-30) and MO-
neg (nontargeting antisense oligo) were purchased from
Gene Tools, LLC (Philomath, OR). Fluorescein-labeled
negative control morpholino (Gene Tools, LLC) and TEX
615elabeled negative control siRNA (IDT, San Jose, CA)
were used to assess transfection efﬁciency. Lipofectamine
RNAiMAX (6 mmol/L; Life Technologies) and Endo-Porter
(Gene Tools, LLC) were used for the transfection of the
miRNA mimics and morpholino oligos, respectively,
according to the manufacturer’s protocols. Cells were
transfected for 48 to 72 hours and maintained under normal
growth conditions before using for invasion assays.
EVT Cell Treatments for Invasion Assays
EVTs were cultured as previously described and plated at
1  105 cells per well in 6-well plates. Experiments
investigating the involvement of the mitogen-activated
protein kinase (MAPK) pathway in trophoblast invasion
were performed by transfecting EVTs with miR-210 for 48
hours, followed by treatment with 50 mmol/L MAPK/
extracellular signaleregulated kinase (ERK) kinase (MEK)
1/2especiﬁc inhibitor, U0126 (Calbiochem, Gibbstown,
NJ), for 1 hour before the start of the invasion assay and for
72 hours during the invasion assay. MEK1/2 inhibitorajp.amjpathol.org - The American Journal of Pathology
Elevated miR-210 Predicts Preeclampsiavehicle control [dimethyl sulfoxide (DMSO)]-treated EVTs
was included in these experiments. The cells were then
plated into chambers for the invasion assay.
Matrigel Invasion Assay
The invasiveness of primary EVT cells through an extra-
cellular matrix was measured using a commercially avail-
able cell invasion assay kit (Chemicon, Temecula, CA).
Brieﬂy, 300 mL of 1  106 EVT cells/mL suspensions were
plated onto 8-mm pore size ECMatrix gel-coated cell culture
inserts in 24-well plates. After 72 hours, the noninvading
cells and the ECMatrix gel from the upper surface of the
inserts were removed using a cotton-tipped swab. Invasive
cells on the lower surface of the membrane were stained
with 0.2% crystal violet for 20 minutes. The membranes
were mounted onto microscope slides. Stained cells from
ﬁve random microscope ﬁelds (at 20 magniﬁcation) were
imaged, counted, and analyzed. Data from experiments
measuring EVT invasion are expressed as a percentage of
control.
Case-Control Study
With Institutional Review Board approval, a case-control
study (Preeclampsia: Mechanisms and Consequences) was
performed between March 2005 and October 2009 at the
Hospital of the University of Pennsylvania (Philadelphia,
PA). Controls were deﬁned as women without
hypertension-related complications who presented for
delivery at term (37 gestational weeks). Cases were
identiﬁed based on prespeciﬁed maternal criteria, according
to standard American College of Obstetricians and Gyne-
cologists criteria. A diagnosis of preeclampsia is deﬁned as
elevated blood pressure (140/90 mm Hg on two
measurements 6 hours apart), with 1þ proteinuria (0-
trace protein for gestational hypertension (GHTN). Based
on these prespeciﬁed criteria, case eligibility was deter-
mined at enrollment by the study investigators and not by
the treating physician. Within 24 hours of enrollment into
the study, before delivery, peripheral blood samples were
collected from all pregnant patients. After sitting at room
temperature for 30 to 60 minutes, samples were centrifuged
at 3400 rpm (1000  g) (Clay Adams Sero-fuge 2001, BD
Biosciences, San Jose, CA) rpm for 20 minutes. Serum was
extracted from whole blood and stored at 80C until the
analyses were performed. miR-210 levels were assessed by
quantitative real time PCR (qPCR), as noted later. Clinical
information, including race, body mass index (BMI) at ﬁrst
prenatal visit, maternal age, and other maternal and prenatal
factors, were abstracted from the patient’s medical record.
Prospective Cohort
To assess if miR-210 expression can predict the develop-
ment of a hypertensive disorder of pregnancy months beforeThe American Journal of Pathology - ajp.amjpathol.orgthe onset of clinical symptoms, a nested case-control study
from a prospective cohort was performed. This cohort is an
Institutional Review Boardeapproved prospective cohort of
low-risk women (The Placenta Study) at the Hospital of the
University of Pennsylvania. Pregnant women, with
singleton gestations, presenting for fetal aneuploidy
screening were eligible for enrollment. Maternal serum was
obtained at the second-trimester blood draw (15 to 20
weeks) and stored at 80C until use. After delivery,
medical records were reviewed and women with a hyper-
tensive disorder (preeclampsia or GHTN) or controls
(women delivering at term with no evidence of any hyper-
tensive disorder of pregnancy) were identiﬁed. A diagnosis
of preeclampsia or GHTN was conﬁrmed by the study
investigator (N.S.). Controls were randomly selected from
the same cohort. For this study, women with chronic
hypertension were excluded. Clinical information, including
race, BMI at ﬁrst prenatal visit, maternal age, and other
maternal and prenatal factors, was abstracted from the
patient’s medical record. miR-210 levels were assessed by
qPCR, as noted later. Statistical analyses for clinical studies/
univariate analyses of categorical data were performed
using c2 or Fisher’s exact tests, as appropriate. Means were
compared using Student’s t-test and one-way analysis of
variance, whereas medians were compared using Wilcoxon-
rank-sum and Kruskal-Wallis tests. If statistical signiﬁcance
was reached, then a pairwise comparison by the Student-
Newman-Keuls test was performed. Multivariable logistic
regression was performed to model the association between
miR-210 and disease state controlling for confounders.
Finally, areas under the receiver-operator curve (AUC) to
determine the test characteristics of miR-210 to predict
disease state were calculated and compared. P < 0.05 was
considered statistically signiﬁcant for all analyses. All
arithmetic means  SEM are presented.
miRNA Extraction, cDNA Generation, and qPCR
Total RNA, including miRNAs and other small RNAs, was
extracted from serum samples via phenol/chloroform
extraction, followed by column-based puriﬁcation. Brieﬂy,
750 mL of TRIzol reagent (Life Technologies) was added to
each 50 mL sample of serum. To this, 1 mg of carrier RNA
(MS2 bacteriophage total RNA; Roche, Indianapolis, IN,
catalog 10165948001) was added. Chloroform (160 mL) was
then added to each sample and mixed vigorously for 15
seconds. The samples were then transferred to a phase lock
gel tube (50, 2302830), and spun at 12,000 g for 15 minutes
at 4C. The resulting aqueous phase was carefully removed
and puriﬁed using Qiagen’s miRNeasy kit (Qiagen, Valencia,
CA), following the manufacturer’s protocol for total RNA
isolation. The RNAwas eluted in 30 mL of RNase-free water.
cDNA was generated from 10 mL of the isolated miRNA
using the miScript Reverse Transcription II kit (Qiagen), and
qPCR was performed on the 7900HT Real-Time PCR
System (Life Technologies) using the miScript SYBR Green1439
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Figure 1 miR-210 regulates trophoblast invasion. Results from invasion
assay of extravillous trophoblast (EVT) cells transfected with miR-210
mimic (A) or inhibitor (B). Values are means  SEM. n Z 6 (A); n Z 3
(B). MO-neg, morpholino-negative control; MO-210, morpholino antisense
oligo to miR-210. *P  0.05.
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Figure 2 miR-210 regulation of extravillous trophoblast (EVT) invasion
is MAPK/ERK dependent. Invasion assay of EVT cells transfected with
miR-210 and treated with the MEK inhibitor, U0126. Negative U0126
columns represent DMSO vehicle-controls. Values are means  SEM (nZ 3).
**P  0.01.
Anton et alPCR kit (Qiagen), according to the manufacturer’s protocols.
The DDCT method was used for relative expression quanti-
ﬁcation using the RQ manager software version 2.4 (Life
Technologies). The endogenous reference, RNU6B, was
used for miRNA quantiﬁcation. All primer sets were
purchased from Qiagen: miR-210 (MS00003801) and
RNU6B (MS0001400).
Statistical Analysis
Statistical analyses for all in vitro experiments were per-
formed with Sigma Stat Software version 3.5 (Statistical
Package for the Social Sciences Inc., Chicago, IL). For data
that were normally distributed, one-way analysis of variance
was used. If statistical signiﬁcance was reached (P < 0.05),
then pairwise comparison with a Student-Newman-Keuls
test was performed.
Results
miR-210 Regulates Trophoblast Invasion
EVT invasion is crucial for proper implantation, and defects in
this process have been associated with preeclampsia. Hence,
we examined the role of miR-210 in EVT invasiveness. EVTs
transfected with an miR-210 mimic had a signiﬁcant decrease
in invasion (approximately 60%) (P < 0.0001) relative to the
mock and negative control transfected cells (Figure 1A).
Transfection efﬁciency was conﬁrmed via qPCR of miR-210
and ﬂuorescent microscopy of cells transfected with a ﬂuo-
rescently labeled siRNA (Supplemental Figure S1, A and B).
Next,we tested the effect of inhibiting endogenousmiR-210 on
trophoblast invasion using an antisense morpholino (MO).
EVTs transfected with MO-210 showed a 20% increase in
invasion when compared with both mock and negative control
transfected EVTs (P Z 0.03) (Figure 1B). Transfection efﬁ-
ciency was conﬁrmed via ﬂuorescent microscopy of cells
transfected with a ﬂuorescently labeled morpholino oligo
(Supplemental Figure S1B). Representative images of stained
membranes from the invasion assays are shown in1440Supplemental Figures S2 and S3. Together, these data strongly
suggest that miR-210 inhibits trophoblast invasion.
miR-210 Inhibition of Trophoblast Invasion Is
Mediated by the ERK/MAPK Pathway
We previously demonstrated a role for ERK signaling in the
regulation of trophoblast invasion.26 Hence, we tested if
miR-210 inhibition of trophoblast invasion was mediated by
the ERK/MAPK pathway. Treatment of EVTs with the
MEK1/2 inhibitor, U0126, blocked the inhibitory effect of
miR-210 on invasion by 40% compared with DMSO
(vehicle control; P < 0.0001) (Figure 2). Representative
images of stained membranes from the invasion assays are
shown in Supplemental Figure S4. Hence, this suggested
that miR-210 inhibited trophoblast invasion, in part, through
the ERK signaling pathway.
Case-Control Study
Serum miR-210 Expression Is Increased in Women with
Hypertensive Disorders of Pregnancy
We measured serum miR-210 expression in women with
(nZ 40) and without (nZ 33) HDP (including preeclampsia
and GHTN). Demographic characteristics are detailed in
Table 1. The median expression of miR-210 was 1.6-fold
higher in cases than controls (P Z 0.001) (Figure 3A).
For each 5 U increase in miR-210, the odds of HDP
increased 36-fold (95% CI 3.8 to 340.3; P Z 0.002).
Controlling for potential confounders, including maternal
age, BMI, race, and parity, the odds of HDP increased
25-fold (95% CI 2.4 to 245.3; P Z 0.007) for each 5 U
increase in miR-210. Including these demographic variables
increased the predictive ability of the model (AUC, 0.81
versus 0.72) (Figure 3B).ajp.amjpathol.org - The American Journal of Pathology
Table 1 Term Case-Control Study Patient Demographics
Demographic Variables
CNTL
(N Z 34)
GHTN
(N Z 7)
PEC
(N Z 33)
P value CNTL
vs GHTN þ PEC
P value CNTL
vs PEC
African American 29 (85) 5 (71) 28 (85) 0.75 0.96
Maternal age at delivery date 26.2 (6.7) 28.9 (8.3) 25.5 (7.5) 0.95 0.69
Nulliparous: no prior pregnancy with GA >16 weeks 9 (26) 4 (57) 20 (61) 0.004 0.005
BMI at ﬁrst prenatal visit 29.3 (7.7) 33.5 (6.3) 27.9 (7.1) 0.79 0.47
Data are given as number (percentage) for discrete variables and mean (SD) for continuous demographic variables by pregnancy-induced hypertension
diagnosis among the 74 women without chronic hypertension in the term case-control study. P values are based on the c2 test for discrete variables or the
t-test for continuous variables.
CNTL, control; GA, gestational age; PEC, preeclampsia.
Elevated miR-210 Predicts PreeclampsiaProspective Cohort
Serum miR-210 Expression Is Increased in Women Destined
to Develop a Hypertensive Disorder of Pregnancy Months
before the Clinical Onset of Symptoms
Next, we sought to determine whether serum miR-210
expression could predict HDP months before the onset of
clinical symptoms. We measured serum miR-210 expres-
sion in women with (n Z 41) and without (n Z 56) HDP.
Demographic characteristics are detailed in Table 2. The
median expression of miR-210 was increased 5.3-fold in
women who eventually developed HDP compared with
those who did not (P Z 0.003) (Figure 3C). For each 5-U
increase in miR-210, the odds of HDP increased 1.8-fold
(95% CI 1.3 to 2.6; P Z 0.001). Controlling for race,0
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Figure 3 miR-210 expression is up-regulated in maternal serum in
hypertensive disorders of pregnancy. A: Relative serum expression of miR-
210 in case-control study (third trimester). Points represent individual
samples. Black horizontal lines are the medians of the respective groups.
The median of the control group is set to 1. B: Receiver-operator curve
(ROC) showing speciﬁcity and sensitivity of miR-210 as a classiﬁer for the
disease state. C and D: Similar to A and B, but with second-trimester serum
samples. ROC curves in B and D are corrected for maternal age, BMI, race,
and parity.
The American Journal of Pathology - ajp.amjpathol.orgtobacco use, BMI, and parity, the odds of HDP increased
2.7-fold (95% CI 1.6 to 4.6; P < 0.0001) for every 5-U
increase of miR-210. When analyses were limited to only
those women with the most severe phenotype (ie, only
women with preeclampsia but not GHTN), each 5-U
increase in miR-210 increased the odds of preeclampsia
fourfold (95% CI 1.8 to 8.7; P < 0.0001; AUC Z 0.89)
(Figure 3D), controlling for the same clinical variables.
Discussion
In this study, we provide evidence for a molecular mecha-
nism by which miR-210 may alter trophoblast invasion, lead
to the development of HDP, and demonstrate that miR-210
may be an accurate biomarker for hypertensive disorders of
pregnancy. The increased expression of miR-210 in the
placenta of women with preeclampsia suggests a possible
functional role in the pathophysiological characteristics of
this disease. In the placenta, miR-210 is primarily expressed
in the villous and extravillous trophoblasts, with stronger in
situ evidence in the latter.31 Furthermore, multiple studies
have shown increased miR-210 expression in placental
cells, such as BeWo, JEG-3, Swan 71, JAR, and cyto-
trophoblasts, exposed to hypoxia (1% to 2% O2).
24,31,32
Interestingly, in a study done by Ishibashi et al,32 miR-
210 expression was found to be highest in the trophoblast
layer of the placenta (when compared with villous stroma
and fetal endothelium). Hence, an increasing number of
studies are attempting to determine the function of miR-210
in the placenta. In a study by Muralimanoharan et al,33
increased expression of miR-210 was found to decrease
mitochondrial respiration and up-regulate reactive oxygen
species in preeclampsia, suggesting a role for miR-210 in
placental dysfunction. In our study, miR-210 repressed
extravillous trophoblast invasion. Our results support
a study done by Zhang et al,24 which found that miR-210
repressed cytotrophoblast invasion and migration. Extra-
villous trophoblasts are the cells that actually invade the
uterine spiral arteries soon after embryo implantation.
Therefore, our ﬁndings suggest a role for miR-210 in the
regulation of trophoblast invasion during early pregnancy.
Interestingly, a study by Lee et al31 suggested that miR-210
up-regulation may contribute to poor trophoblast invasion1441
Table 2 Second-Trimester Case-Control Study Patient Demographics
Demographic Variables
CNTL
(N Z 56)
GHTN
(N Z 21) PEC (N Z 20)
P value CNTL
vs GHTN þ PEC
P value CNTL
vs PEC
Race 0.044 0.26
African American 25 (45) 4 (19) 12 (60)
Asian 11 (20) 1 (5) 1 (5)
White/other 20 (36) 16 (76) 7 (35)
Maternal age at delivery date 29.7 (6.6) 30.4 (7.2) 31.2 (7.5) 0.45 0.40
Smoked tobacco in the ﬁrst trimester 6 (11) 3 (14) 2 (10) 0.87 0.89
Nulliparous: no prior pregnancy with GA >16 weeks 0.18 0.36
No, 1þ prior pregnancy 20 (36) 3 (14) 5 (25)
Yes, ﬁrst pregnancy 18 (32) 9 (43) 5 (25)
Missing 18 (32) 9 (43) 10 (50)
BMI at ﬁrst prenatal visit 24.9 (5.6) 28.5 (6.8) 31.0 (7.3) 0.001 0.003
Data are given as number (percentage) for discrete variables and mean (SD) for continuous demographic variables by pregnancy-induced hypertension
diagnosis among the 97 women without chronic hypertension in the second-trimester case-control study. P values are based on the c2 test for discrete
variables or the t-test for continuous variables.
CNTL, control; GA, gestational age; PEC, preeclampsia.
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homologue. Although our study demonstrates that miR-210
represses invasion, in certain disease states (eg, cancer),
miR-210 has been demonstrated to promote tumor cell
invasion.34,35 The differing molecular effects of miR-210
suggest that miR-210 likely acts in a cell- and disease-
speciﬁc manner. Further research is needed to elucidate
the role of miR-210 in trophoblast function and in the
development of trophoblast-related adverse pregnancy
outcomes.
The molecular mechanism by which miR-210 regulates
trophoblast invasion is likely complex because miRNAs can
target hundreds of genes. We determined that miR-210
inhibition of trophoblast invasion was dependent, at least in
part, on MAPK signaling. In a previous study, we also
found that lipopolysaccharide (LPS) inhibited trophoblast
invasion in an MAPK-dependent manner.26 Interestingly,
LPS activates miR-210 expression in murine macro-
phages.36 Hence, miR-210 may serve as a converging node
for multiple stimuli (including hypoxia and inﬂammation)
that regulate trophoblast invasion. Furthermore, both hyp-
oxia and LPS activate ERK/MAPK signaling in trophoblast
cells.37 This suggests that miR-210 may function upstream
of MAPK, possibly promoting signaling and, consequently,
repressing trophoblast invasion.
Because we determined a functional role for miR-210 in
trophoblast dysfunction and the placenta secretes miRNAs
into maternal circulation during pregnancy,25 we wanted to
assess if serum levels of miR-210 could identify the onset of
preeclampsia. By using our clinical specimens, we found
that miR-210 was elevated in the serum of women with
a diagnosis of preeclampsia compared with women without
disease. Our ﬁnding that miR-210 levels are associated with
the development of HDP corroborated a recent study by
Zhang et al24 in a cohort of Chinese women. However, this
study was limited in that it investigated plasma miR-210
levels in term pregnancies only with a total sample size of144245 patients. Our study, with a larger sample size, conﬁrms
these ﬁndings. Novel to our study, we have demonstrated
that miR-210 levels can predict the future development of
HDP months before the clinical onset of symptoms. To our
knowledge, this is the ﬁrst study to identify a biomarker
with this degree of prediction for the future development of
HDP. The most promising ﬁnding of our study is the ability
of miR-210 to accurately predict the development of
preeclampsia 8 to 12 weeks before the clinical onset of any
symptoms. Although conﬁrmation in larger cohorts is
needed, these results suggest that miR-210 levels might
provide a strong tool for identifying women at risk for HDP
months before the clinical onset of disease. Thus, if vali-
dated, miR-210 might provide the opportunity to offer new
therapeutic strategies to women at risk.
With the hopes of diagnosing preeclampsia before the
development of clinical symptoms, investigators have
focused on identifying early biomarkers for this disease.
Several studies have investigated preeclampsia-associated
pro- and anti-angiogenic factors, including soluble fms-like
tyrosine kinase (sFlt-1), placental growth factor (PlGF), and
soluble endoglin (sENG), as possible serum biomarkers for
this disease.38e44 However, studies on the effectiveness of
these factors as early biomarkers of preeclampsia are some-
what contradictory because some have found altered PlGF,
sFlt-1, and sENG levels in the serum of women who devel-
oped preeclampsia and others found no association.38e41,45,46
Espinoza et al45 performed one of the largest prospective
cohort studies (3348 patients) investigating the predictive
ability of angiogenic factors (along with uterine artery
Doppler velocimetry) to identify patients destined to develop
preeclampsia. Maternal PlGF concentration predicted early-
onset preeclampsia (AUCZ 0.80) and severe preeclampsia
(AUC Z 0.789); however, maternal sFlt-1 levels were
of limited use in the prediction of early-onset (AUCZ 0.49)
and severe (AUC Z 0.54) preeclampsia.45 Another large
(1622 patients) longitudinal cohort study, performed byajp.amjpathol.org - The American Journal of Pathology
Elevated miR-210 Predicts PreeclampsiaKusanovic et al,44 found lower predictive values for sFlt-1
(AUC Z 0.587), PlGF (AUC Z 0.647), and PlGF/sFlt-1
(AUC Z 0.592) in early pregnancy (6 to 15 weeks). Simi-
larly, AUCs were lower in mid-trimester (20 to 25 weeks) for
sFlt-1 (0.524), PlGF (0.650), and PLF/sFlt-1 (0.602).44 In
addition, we have demonstrated in a prospective case-control
study that included 374 patients that sFlt-1, PlGF, and sENG
do not perform well in discriminating cases from controls.46
Alterations in the ratios of angiogenic factors, including
serum sFlt-1 to PlGF, may possibly be more accurate pre-
dictors of preeclampsia across different gestational time
points.42e44 Although somewhat promising, overall, these
biomarkers are not thought to be reliable enough for general
application in predicting preeclampsia.47 Nevertheless, as
previously suggested, a panel of biomarkersmay be needed to
effectively identify women early in pregnancy who are at the
highest risk for developing preeclampsia. Although speciﬁc
interactions between miR-210 and these angiogenic factors
are unknown, future studies could explore if evaluating these
factors together may more accurately predict preeclampsia.
However, if the predictive ability of miR-210, as demon-
strated in this study, is validated in larger prospective cohort
studies, then miR-210 alone may prove to be a useful
biomarker without additional analytes.
Circulating miRNAs have emerged as powerful
biomarkers for human disease.48,49 They are resistant to
degradation and are readily measured from small volumes of
bioﬂuid. miRNAs are released from many tissues/cell types
into the circulation via exosomes and microvesicles.15
Therefore, expression changes in the circulation can proxy
changes in the source tissue(s). For example, the chromo-
some 19 miRNA cluster is expressed predominantly in the
placenta.50 During pregnancy, chromosome 19 miRNA
cluster miRNAs are secreted via exosomes into the maternal
circulation, where they remain highly expressed until
delivery.25 Although the exact origin of miR-210 in the
maternal circulation remains unclear, it is plausible that it is
being released from the placenta. Prior work has demon-
strated that miR-210 is expressed in placental tissues and
that miR-210 levels are increased in the placentas from
preeclamptic women.21e23 However, we cannot exclude
other sources for miR-210 in maternal serum. Because miR-
210 is expressed in endothelial cells and endothelial
dysfunction is posited to contribute to preeclampsia patho-
physiological characteristics,51 release of miR-210 from the
vasculature of pregnant women may be a source of miR-210
in maternal serum.
In all, our results show that elevated levels of miR-210
lead to a decrease in extravillous trophoblast invasion via an
MAPK-dependent mechanism. Also, we demonstrate that
miR-210 has the potential to be a predictive and diagnostic
biomarker for preeclampsia because serum miR-210 is
elevated months before the onset of clinical symptoms.
More studies are needed to understand the source and
function of the elevated miR-210 in preeclampsia and
how this relates to the etiological and pathophysiologicalThe American Journal of Pathology - ajp.amjpathol.orgcharacteristics of the disease. However, our ﬁndings may
provide a new clinical strategy to identify women at risk for
preeclampsia and apply and test intervention strategies to
improve maternal and fetal health outcomes.
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